Postoperative Inflammation: Advances in Treatment Podcast
Supported through an educational grant from Ocular Therapeutix.
This podcast has no credit associated with it.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty have the following financial relationships with commercial interests:
Eric Donnenfeld, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allegro, Allergan, Alcon, Avedro, Avellino Labs, Bausch + Lomb, Blephex, BVI, Carl Zeiss Meditec, CorneaGen, CRST, Dompe, Elenza, EyePoint Pharma, Foresight, Glaukos, Icon Biosciences, Johnson & Johnson Vision, Kala, Katena Lacripen, LensGen, Mati Pharmaceuticals, MDBackline, Merck, Mimetogen, Nanowafer, Novabay, Novartis, Novaliq, Ocular Innovations, Oculis, Odyssey, Omega Ophthalmics, Orasis, Oyster Point Therapeutics, Pfizer, Pogotec, Ocuhub, Omeros, PRN, ReTear, RPS, Shire, Strathspey Crown, Sun, Surface, Tearlab, TLC Laser Centers, Veracity, and Versant Ventures. Speaker’s Bureau: Avedro, CorneaGen, Elenza, EyePoint Pharma, Glaukos, LacriPen, LensGen, Mati Pharmaceuticals, MDBackline, Mimetogen, Novabay, Ocuhub, Ocular Innovations Oculis, Orasis Pogotec, ReTear, RPS, Sarcode, Strathspey Crown, Surface, Tearlab, Veracity, Versant Ventures, and Visionary Ventures.
Inder Paul Singh, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Aerie, Allergan, Alcon, Bausch + Lomb, Carl Zeiss Meditec, Ellex, Eyepoint, Glaukos, iStar, Ivantis, New World Medical, Shire, and Sun. Grant/Research Support: Aerie, Alcon, Ellex, Glaukos, Ivantis, Sensimed, and Sight Sciences.
EDITORIAL SUPPORT DISCLOSURES
Erin K. Fletcher, MIT, director of compliance and education; Susan Gallagher-Pecha, director of client services and project management; Cassandra Richards, director of education development, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Ocular Therapeutix.
By: Eric D. Donnenfeld, MD; and Paul Singh, MD